antibody

Goat anti-TET2 Antibody

MBS421699

0.1 mg

300 USD

polyclonal

goat

nonconjugated

human, mouse, dog

immunohistochemistry, enzyme immunoassay

Antibody

Goat anti-TET2 Antibody

TET2

TET2; tet oncogene family member 2; FLJ20032; KIAA1546; MGC125715; OTTHUMP00000161869; TET2 antibody; tet oncogene family member 2 antibody; FLJ20032 antibody; KIAA1546 antibody; MGC125715 antibody; OTTHUMP00000161869 antibody

methylcytosine dioxygenase TET2 isoform a; Methylcytosine dioxygenase TET2; methylcytosine dioxygenase TET2; tet methylcytosine dioxygenase 2

TET2

TET2; TET2; MDS; KIAA1546; KIAA1546

TET2_HUMAN

Polyclonal

Goat

Tested: Human; Expected from sequence similarity: Human, Mouse, Dog

2002

PHPQSNNDQQREGSF

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA), Immunohistochemistry (IHC)

Peptide ELISA: Antibody detection limit dilution 1: 16000. Immunohistochemistry: In paraffin embedded Human Spleen shows nuclear staining in select splenocytes. This antibody has also been used successfully on Human Brain sections: Orr et al, PLoS One.2012;7(7): e41036.2012 Jul 19. PMID: 22829908. Recommended concentration, 2-6ug/ml.

Immunogen: Peptide with sequence C-PHPQSNNDQQREGSF, from the internal region of the protein sequence according to NP_001120680.1; NP_060098.3. Epitope: Internal region

Note: This antibody is expected to recognize both reported isoforms (NP_001120680.1; NP_060098.3).

187761317

NP_001120680.1

NM_001127208.2

133,481 Da

Epigenetic Regulation Of Gene Expression Pathway (1269734); Gene Expression Pathway (1269649); TET1,2,3 And TDG Demethylate DNA Pathway (1269736)

The protein encoded by this gene is a methylcytosine dioxygenase that catalyzes the conversion of methylcytosine to 5-hydroxymethylcytosine. The encoded protein is involved in myelopoiesis, and defects in this gene have been associated with several myeloproliferative disorders. Two variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2011]

TET2: Catalyzes the conversion of methylcytosine (5mC) to 5- hydroxymethylcytosine (hmC). Plays an important role in myelopoiesis. The clear function of 5-hydroxymethylcytosine (hmC) is still unclear but it may influence chromatin structure and recruit specific factors or may constitute an intermediate component in cytosine demethylation. TET2 is frequently mutated in myeloproliferative disorders (MPD). These constitute a heterogeneous group of disorders, also known as myeloproliferative diseases or myeloproliferative neoplasms (MPN), characterized by cellular proliferation of one or more hematologic cell lines in the peripheral blood, distinct from acute leukemia. Included diseases are: essential thrombocythemia, polycythemia vera, primary myelofibrosis (chronic idiopathic myelofibrosis). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Defects in TET2 are a cause of polycythemia vera (PV). A myeloproliferative disorder characterized by abnormal proliferation of all hematopoietic bone marrow elements, erythroid hyperplasia, an absolute increase in total blood volume, but also by myeloid leukocytosis, thrombocytosis and splenomegaly. TET2 is frequently mutated in systemic mastocytosis; also known as systemic mast cell disease. A condition with features in common with myeloproliferative diseases. It is a clonal disorder of the mast cell and its precursor cells. The clinical symptoms and signs of systemic mastocytosis are due to accumulation of clonally derived mast cells in different tissues, including bone marrow, skin, the gastrointestinal tract, the liver, and the spleen. Defects in TET2 are a cause of myelodysplastic syndrome (MDS). A heterogeneous group of closely related clonal hematopoietic disorders. All are characterized by a hypercellular or hypocellular bone marrow with impaired morphology and maturation, dysplasia of the myeloid, megakaryocytic and/or erythroid lineages, and peripheral blood cytopenias resulting from ineffective blood cell production. Included diseases are: refractory anemia (RA), refractory anemia with ringed sideroblasts (RARS), refractory anemia with excess blasts (RAEB), refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS). Chronic myelomonocytic leukemia (CMML) is a myelodysplastic/myeloproliferative disease. Myelodysplastic syndromes are considered a premalignant condition in a subgroup of patients that often progresses to acute myeloid leukemia (AML). Bone marrow samples from patients display uniformly low levels of hmC in genomic DNA compared to bone marrow samples from healthy controls as well as hypomethylation relative to controls at the majority of differentially methylated CpG sites. Belongs to the TET family. 3 isoforms of the human protein are produced by alternative splicing. Protein type: Oxidoreductase; Tumor suppressor; EC 1.14.11.n2. Chromosomal Location of Human Ortholog: 4q24. Molecular Function: DNA binding; ferrous iron binding; protein binding; zinc ion binding. Biological Process: 5-methylcytosine catabolic process; cell cycle; cytosine metabolic process; hemoglobin metabolic process; kidney development; myeloid cell differentiation; myeloid progenitor cell differentiation; positive regulation of transcription from RNA polymerase II promoter; post-embryonic development; protein amino acid O-linked glycosylation; response to organic cyclic substance; spleen development. Disease: Myelodysplastic Syndrome

0.1 mg

300 USD